Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

PURPOSE: To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. METHODS: ER analyses were conducted using pooled...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrissey, Kari M., Marchand, Mathilde, Patel, Hina, Zhang, Rong, Wu, Benjamin, Phyllis Chan, H., Mecke, Almut, Girish, Sandhya, Jin, Jin Y., Winter, Helen R., Bruno, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820606/
https://www.ncbi.nlm.nih.gov/pubmed/31542806
http://dx.doi.org/10.1007/s00280-019-03954-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820606/
https://www.ncbi.nlm.nih.gov/pubmed/31542806
http://dx.doi.org/10.1007/s00280-019-03954-8

Ejemplares similares